The BRAF mutation is associated with the prognosis in colorectal cancer

被引:31
作者
Ahn, Tae Sung [1 ]
Jeong, Dongjun [2 ]
Son, Myoung Won [1 ]
Jung, Haeil [1 ]
Park, Soyoung [3 ]
Kim, Hyungjoo [3 ]
Bae, Sang Byung [4 ]
Kim, Han Jo [4 ]
Jeon, Young-Woo [5 ]
Lee, Moon Soo [1 ]
Baek, Moo-Jun [1 ]
机构
[1] Soonchunhyang Univ Korea, Dept Surg, Coll Med, Cheonan 330722, Chungcheongnam, South Korea
[2] Soonchunhyang Univ Korea, Med Sci Res Inst, Cheonan 330722, Chungcheongnam, South Korea
[3] Soonchunhyang Univ Korea, Dept Pathol, Coll Med, Cheonan 330722, Chungcheongnam, South Korea
[4] Soonchunhyang Univ Korea, Dept Hematol & Oncol, Coll Med, Cheonan 330722, Chungcheongnam, South Korea
[5] Catholic Univ Korea, Dept Hematol, Catholic Blood & Marrow Transplantat Ctr, Coll Med, Seoul, South Korea
关键词
BRAF; KRAS; Colorectal cancer; PNA clamping PCR; Survival; MICROSATELLITE INSTABILITY STATUS; ISLAND METHYLATOR PHENOTYPE; KIRSTEN RAS MUTATIONS; COLON-CANCER; STAGE-III; K-RAS; MISMATCH-REPAIR; V600E MUTATION; POOR SURVIVAL; B-RAF;
D O I
10.1007/s00432-014-1735-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Two members of the Ras/Raf signaling pathway, KRAS and B-raf, are suspected to be involved in the stepwise progression of colorectal cancer (CRC) tumorigenesis. We compared the KRAS and BRAF mutation status of CRC patients with their clinicopathological characteristics and examined the effect of mutation status on survival rates. DNA was extracted from 164 samples, and the mutation statuses of KRAS and BRAF were assessed using peptide PNA clamp real-time PCR method. The presences of mutation were compared with clinicopathological factors and 5-year survival rate. Among the 164 CRC cases, KRAS mutation as detected in 71 cases (43.3 %), respectively, with no relationship with clinicopathological factors of the patients. On Kaplan-Meier survival analysis, KRAS mutation was not significantly associated with survival (p = 0.971). BRAF mutation was detected in 26 cases (15.9 %) and not associated with clinicopathological factors of the patients. However, the 5-year survival rate of BRAF mutations was significantly decreased (p = 0.02). The presence of KRAS mutation did not correlate with the various clinicopathological factors of CRC patients or the survival rate. However, the survival rate was reduced in BRAF-mutated CRC patients. Therefore, BRAF mutation could be an important prognostic factor in CRC patients.
引用
收藏
页码:1863 / 1871
页数:9
相关论文
共 41 条
[1]   Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].
Amado, Rafael G. ;
Wolf, Michael ;
Peeters, Marc ;
Van Cutsem, Eric ;
Siena, Salvatore ;
Freeman, Daniel J. ;
Juan, Todd ;
Sikorski, Robert ;
Suggs, Sid ;
Radinsky, Robert ;
Patterson, Scott D. ;
Chang, David D. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634
[2]   K-ras mutations and prognosis in large-bowel carcinomas [J].
Andersen, SN ;
Lovig, T ;
Breivik, J ;
Lund, E ;
Gaudernack, G ;
Meling, GI ;
Rognum, TO .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1997, 32 (01) :62-69
[3]   Kirsten ras mutations in patients with colorectal cancer:: the 'RASCAL II' study [J].
Andreyev, HJN ;
Norman, AR ;
Cunningham, D ;
Oates, J ;
Dix, BR ;
Iacopetta, BJ ;
Young, J ;
Walsh, T ;
Ward, R ;
Hawkins, N ;
Beranek, M ;
Jandik, P ;
Benamouzig, R ;
Jullian, E ;
Laurent-Puig, P ;
Olschwang, S ;
Muller, O ;
Hoffmann, I ;
Rabes, HM ;
Zietz, C ;
Troungos, C ;
Valavanis, C ;
Yuen, ST ;
Ho, JWC ;
Croke, CT ;
O'Donoghue, DP ;
Giaretti, W ;
Rapallo, A ;
Russo, A ;
Bazan, V ;
Tanaka, M ;
Omura, K ;
Azuma, T ;
Ohkusa, T ;
Fujimori, T ;
Ono, Y ;
Pauly, M ;
Faber, C ;
Glaesener, R ;
de Goeij, AFPM ;
Arends, JW ;
Andersen, SN ;
Lövig, T ;
Breivik, J ;
Gaudernack, G ;
Clausen, OPF ;
De Angelis, P ;
Meling, GI ;
Rognum, TO ;
Smith, R .
BRITISH JOURNAL OF CANCER, 2001, 85 (05) :692-696
[4]   Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study [J].
Andreyev, HJN ;
Norman, AR ;
Cunningham, D ;
Oates, JR ;
Clarke, PA .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (09) :675-684
[5]   Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers [J].
Barault, Ludovic ;
Veyrie, Nicolas ;
Jooste, Valerie ;
Lecorre, Delphine ;
Chapusot, Caroline ;
Ferraz, Jean-Marc ;
Lievre, Astrid ;
Cortet, Marion ;
Bouvier, Anne-Marie ;
Rat, Patrick ;
Roignot, Patrick ;
Faivre, Jean ;
Laurent-Puig, Pierre ;
Piard, Francoise .
INTERNATIONAL JOURNAL OF CANCER, 2008, 122 (10) :2255-2259
[6]   Determinants of RASistance to anti-epidermal growth factor receptor agents [J].
Baselga, Jose ;
Rosen, Neal .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1582-1584
[7]   Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies [J].
Benvenuti, Silvia ;
Sartore-Bianchi, Andrea ;
Di Nicolantonio, Federica ;
Zanon, Carlo ;
Moroni, Mauro ;
Veronese, Silvio ;
Siena, Salvatore ;
Bardelli, Alberto .
CANCER RESEARCH, 2007, 67 (06) :2643-2648
[8]   p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer [J].
Bouzourene, H ;
Gervaz, P ;
Cerottini, JP ;
Benhattar, J ;
Chaubert, P ;
Saraga, E ;
Pampallona, S ;
Bosman, FT ;
Givel, JC .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (08) :1008-1015
[9]  
BURKE LC, 1992, ONCOGENE, V7, P783
[10]   More extensive nodal dissection improves survival for stages I to III of colon cancer - A population-based study [J].
Chen, Steven L. ;
Bilchik, Anton J. .
ANNALS OF SURGERY, 2006, 244 (04) :602-610